These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 12485957)

  • 1. Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.
    Mattiuz EL; Ponsler GD; Barbuch RJ; Wood PG; Mullen JH; Shugert RL; Li Q; Wheeler WJ; Kuo F; Conrad PC; Sauer JM
    Drug Metab Dispos; 2003 Jan; 31(1):88-97. PubMed ID: 12485957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
    Sauer JM; Ponsler GD; Mattiuz EL; Long AJ; Witcher JW; Thomasson HR; Desante KA
    Drug Metab Dispos; 2003 Jan; 31(1):98-107. PubMed ID: 12485958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical pharmacokinetics of atomoxetine.
    Sauer JM; Ring BJ; Witcher JW
    Clin Pharmacokinet; 2005; 44(6):571-90. PubMed ID: 15910008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs.
    Beconi MG; Reed JR; Teffera Y; Xia YQ; Kochansky CJ; Liu DQ; Xu S; Elmore CS; Ciccotto S; Hora DF; Stearns RA; Vincent SH
    Drug Metab Dispos; 2007 Apr; 35(4):525-32. PubMed ID: 17220241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro.
    Lan T; Hu XX; Liang BQ; Pan WH; Zhou Q; Yuan LJ; Hu GX
    Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):261-268. PubMed ID: 27207674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
    Ring BJ; Gillespie JS; Eckstein JA; Wrighton SA
    Drug Metab Dispos; 2002 Mar; 30(3):319-23. PubMed ID: 11854152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA; Desager JP; Desante KA; Frye RF; Witcher J; Long AJ; Sauer JM; Golnez JL; Smith BP; Thomasson HR; Horsmans Y
    Clin Pharmacol Ther; 2003 Mar; 73(3):178-91. PubMed ID: 12621383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of paroxetine on the pharmacokinetics of atomoxetine and its metabolites in different CYP2D6 genotypes.
    Jung EH; Lee YJ; Kim DH; Kang P; Lim CW; Cho CK; Jang CG; Lee SY; Bae JW
    Arch Pharm Res; 2020 Dec; 43(12):1356-1363. PubMed ID: 33245517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolism of 14C-iodochlorhydroxyquin in the dog and the rat.
    Jurima M; Kalow W; Inaba T
    J Pharmacobiodyn; 1984 Mar; 7(3):164-70. PubMed ID: 6235361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolism and disposition of 14C-granisetron in rat, dog and man after intravenous and oral dosing.
    Clarke SE; Austin NE; Bloomer JC; Haddock RE; Higham FC; Hollis FJ; Nash M; Shardlow PC; Tasker TC; Woods FR
    Xenobiotica; 1994 Nov; 24(11):1119-31. PubMed ID: 7701853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disposition and metabolism of olanzapine in mice, dogs, and rhesus monkeys.
    Mattiuz E; Franklin R; Gillespie T; Murphy A; Bernstein J; Chiu A; Hotten T; Kassahun K
    Drug Metab Dispos; 1997 May; 25(5):573-83. PubMed ID: 9152596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism and disposition of GTS-21, a novel drug for Alzheimer's disease.
    Azuma R; Komuro M; Korsch BH; Andre JC; Onnagawa O; Black SR; Mathews JM
    Xenobiotica; 1999 Jul; 29(7):747-62. PubMed ID: 10456692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of labetalol by animals and man.
    Martin LE; Hopkins R; Bland R
    Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and metabolism of TR-14035, a novel antagonist of a4ss1/a4ss7 integrin mediated cell adhesion, in rat and dog.
    Tsuda-Tsukimoto M; Ogasawara Y; Kume T
    Xenobiotica; 2005 Apr; 35(4):373-89. PubMed ID: 16019958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Absorption and disposition of ranitidine hydrochloride in rat and dog.
    Eddershaw PJ; Chadwick AP; Higton DM; Fenwick SH; Linacre P; Jenner WN; Bell JA; Manchee GR
    Xenobiotica; 1996 Sep; 26(9):947-56. PubMed ID: 8893041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics, metabolism, and excretion of the glycogen synthase kinase-3 inhibitor LY2090314 in rats, dogs, and humans: a case study in rapid clearance by extensive metabolism with low circulating metabolite exposure.
    Zamek-Gliszczynski MJ; Abraham TL; Alberts JJ; Kulanthaivel P; Jackson KA; Chow KH; McCann DJ; Hu H; Anderson S; Furr NA; Barbuch RJ; Cassidy KC
    Drug Metab Dispos; 2013 Apr; 41(4):714-26. PubMed ID: 23305709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excretion and metabolism of the antihypertensive agent, RWJ-26240 (McN-5691) in dogs.
    Wu WN; Masucci JA; Caldwell GW; Carson JR
    Drug Metab Dispos; 1998 Feb; 26(2):115-25. PubMed ID: 9456297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.